Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas L Schwartz

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Psychopharmacology Bulletin|October 26, 2002
The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case seriesThomas L Schwartz
Mens Sana Monographs|May 17, 2013
Psychopharmacological Practice: The DSM Versus The BrainThomas L Schwartz
The Journal of Clinical Psychiatry|June 2, 2016
Why is mechanism of action important in antidepressant treatment?Thomas L Schwartz
Mens Sana Monographs|February 18, 2011
Psychopharmacology Today: Where are We and Where Do We Go From Here?Thomas L Schwartz
CNS Spectrums|November 21, 2013
A neuroscientific update on monoamine oxidase and its inhibitorsThomas L Schwartz
Expert Opinion on Pharmacotherapy|October 6, 2006
Tiagabine in anxiety disordersThomas L Schwartz, Nikhil Nihalani
Drugs in Context|January 17, 2014
Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizonThomas L Schwartz, Viral Goradia
Psychopharmacology Bulletin|October 17, 2003
Psychotropic drug-induced weight gain alleviated with orlistat: a case seriesThomas L Schwartz, Mark Beale
International Journal of Emergency Mental Health|October 28, 2014
Adolescent angst or true intent? Suicidal behavior, risk, and neurobiological mechanisms in depressed children and teenagers taking antidepressantsJulia Morrison, Thomas L Schwartz
Mens Sana Monographs|December 30, 2016
Neural Implications of Psychotherapy, Pharmacotherapy, and Combined Treatment in Major Depressive DisorderThomas L Schwartz, Daniel Santarsieri
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Psychopharmacology Bulletin|October 26, 2002
The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case seriesThomas L Schwartz
Mens Sana Monographs|May 17, 2013
Psychopharmacological Practice: The DSM Versus The BrainThomas L Schwartz
The Journal of Clinical Psychiatry|June 2, 2016
Why is mechanism of action important in antidepressant treatment?Thomas L Schwartz
Mens Sana Monographs|February 18, 2011
Psychopharmacology Today: Where are We and Where Do We Go From Here?Thomas L Schwartz
CNS Spectrums|November 21, 2013
A neuroscientific update on monoamine oxidase and its inhibitorsThomas L Schwartz
Expert Opinion on Pharmacotherapy|October 6, 2006
Tiagabine in anxiety disordersThomas L Schwartz, Nikhil Nihalani
Drugs in Context|January 17, 2014
Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizonThomas L Schwartz, Viral Goradia
Psychopharmacology Bulletin|October 17, 2003
Psychotropic drug-induced weight gain alleviated with orlistat: a case seriesThomas L Schwartz, Mark Beale
International Journal of Emergency Mental Health|October 28, 2014
Adolescent angst or true intent? Suicidal behavior, risk, and neurobiological mechanisms in depressed children and teenagers taking antidepressantsJulia Morrison, Thomas L Schwartz
Mens Sana Monographs|December 30, 2016
Neural Implications of Psychotherapy, Pharmacotherapy, and Combined Treatment in Major Depressive DisorderThomas L Schwartz, Daniel Santarsieri
Pageof 5